Scynexis pulls vaginal infection tablet from shelves, pauses ongoing trials on the heels of contamination risk concerns
Scynexis pulled its vaginal infection drug Brexafemme (ibrexafungerp) from the market and placing a temporary hold on ongoing clinical trials due to contamination risk issues spotted by its product licensor GSK. Ibrexafungerp will only be made available again once there is a mitigation strategy and resupply plan in place.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.